Clinical Trials

Clinical data on Pharmion's Vidaza (azacitidine for injectable suspension) presented at ASCO

Published in Blood Weekly, July 6th, 2006

Pharmion Corporation (PHRM) reported findings from seven studies investigating the use of Vidaza (azacitidine for injectable suspension) in hematologic and solid tumor cancers.

The results of these studies were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.

The seven studies investigate a variety of uses for Vidaza - including alternative dosing schedules, and combination use with approved and/or investigational therapies, such as thalidomide, carboplatin and the histone deacetylase (HDAC) inhibitor valproic acid (VPA). Two of these studies explore the feasibility of the emerging...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry